These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 35489363)

  • 21. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
    Eto M; Takagi T; Kimura G; Fukasawa S; Tamada S; Miura Y; Oya M; Sassa N; Anai S; Nozawa M; Sakai H; Perini R; Yusa W; Ikezawa H; Narita T; Tomita Y
    Cancer Med; 2023 Mar; 12(6):6902-6912. PubMed ID: 36457273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
    Bergerot C; Young Rha S; Pal S; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Lyun Lee J; Sunela K; Ciuleanu T; Heng D; Glen H; Wang J; Bennett L; Pan J; O'Hara K; Puente J
    Oncologist; 2023 Jan; 28(1):59-71. PubMed ID: 35881028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
    Grünwald V; Powles T; Choueiri TK; Hutson TE; Porta C; Eto M; Sternberg CN; Rha SY; He CS; Dutcus CE; Smith A; Dutta L; Mody K; Motzer RJ
    Future Oncol; 2019 Mar; 15(9):929-941. PubMed ID: 30689402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
    Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
    ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
    Van Cutsem E; Amonkar M; Fuchs CS; Alsina M; Özgüroğlu M; Bang YJ; Chung HC; Muro K; Goekkurt E; Benson AB; Sun W; Wainberg ZA; Norquist JM; Chen X; Shih CS; Shitara K
    Gastric Cancer; 2021 Nov; 24(6):1330-1340. PubMed ID: 34363528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
    Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
    J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK;
    Lancet Oncol; 2022 Sep; 23(9):1133-1144. PubMed ID: 36055304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
    Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
    Grünwald V; Powles T; Kopyltsov E; Kozlov V; Alonso-Gordoa T; Eto M; Hutson T; Motzer R; Winquist E; Maroto P; Keam B; Procopio G; Wong S; Melichar B; Rolland F; Oya M; Rodriguez-Lopez K; Saito K; McKenzie J; Porta C
    Eur Urol Oncol; 2023 Aug; 6(4):437-446. PubMed ID: 36720658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
    Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
    N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
    Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
    Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
    Bottomley A; Coens C; Mierzynska J; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Puig S; Ascierto PA; Larkin J; Lorigan PC; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C; Eggermont AMM;
    Lancet Oncol; 2021 May; 22(5):655-664. PubMed ID: 33857414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
    J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.